MMP-2 as a putative biomarker for carcinomatosis in gastric cancer

Hepato-Gastroenterology

Volumn 58, Issue 112, 2011, Pages 2015-2019

  Noh, Sewon ^a   Jung, Jae Joon ^a,b,c   Jung, Minkyu ^a,d,e   Kim, Tae Soo ^a,d   Park, Chan Hee ^a,b,c   Lim, Seung Joon ^a   Jeung, Hei Cheul ^a,d,e   Chung, Hyun Cheol ^a,b,c,d,e   Rha, Sun Young ^a,b,c,d,e  

^a Cancer Metastasis Research Center   (South Korea)

^b National Biochip Research Center   (South Korea)

^c Yonsei University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

Advanced gastric cancer; Biomarker; Body fluid; Carcinomatosis; Matrix metalloproteinase

Indexed keywords

GELATINASE A; GELATINASE B;

ADULT; AGED; ARTICLE; ASCITES FLUID; CARCINOMATOSIS; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOLOGY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PLEURA METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; ZYMOGRAPHY;

ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863232116     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11209     Document Type: Article

References (28)

1. Hohenberger P, Gretschel S: Gastric cancer. Lancet 2003; 362:305-315. (Pubitemid 36936845)
2. Levi F, Lucchini F, Gonzalez JR, Fernandez E, Negri E, La Vecchia C: Monitoring falls in gastric cancer mortality in europe. Ann Oncol 2004; 15:338-345. (Pubitemid 38262637)
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
4. De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M: Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007; 18Suppl6:vi120-123.
5. Runyon BA, Hoefs JC, Morgan TR: Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988; 8:1104-1109.
6. Hayes N, Wayman J, Wadehra V, Scott DJ, Raimes SA, Griffin SM: Peritoneal cytology in the surgical evaluation of gastric carcinoma. Br J Cancer 1999; 79:520-524. (Pubitemid 29046229)
7. Burke EC, Karpeh MS, Jr., Conlon KC, Brennan MF: Peritoneal lavage cytology in gastric cancer: An independent predictor of outcome. Ann Surg Oncol 1998; 5:411-415. (Pubitemid 28367066)
8. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasui T, Yoshimitsu Y, Fushida S, Fujimura T, Nishimura G, Miwa K: Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 1999; 178:256-262. (Pubitemid 29475109)
9. Abe S, Yoshimura H, Tabara H, Tachibana M, Monden N, Nakamura T, Nagaoka S: Curative resection of gastric cancer: Limitation of peritoneal lavage cytology in predicting the outcome. J Surg Oncol 1995; 59:226-229.
10. de Manzoni G, Verlato G, Di Leo A, Tomezzoli A, Pedrazzani C, Pasini F, Piubello Q, Cordiano C: Peritoneal cytology does not increase the prognostic information provided by tnm in gastric cancer. World J Surg 2006; 30:579-584.
11. Ohtsuka T, Sato S, Kitajima Y, Tanaka M, Nakafusa Y, Miyazaki K: False-positive findings for tumor markers after curative gastrectomy for gastric cancer. Dig Dis Sci 2008; 53:73-79. (Pubitemid 350265652)
12. Caspar MJ, Arribas I, Coca MC, Diez-Alonso M: Prognostic value of carcinoembryonic antigen, ca 19-9 and ca 72-4 in gastric carcinoma. Tumour Biol 2001; 22:318-322. (Pubitemid 32823950)
13. Dragutinovic V, Izrael-Zivkovic L, Radovanovic N: Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer. Dig Dis Sci 2009; 54:1203-1207.
14. Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon YS, Davis GE, Brooks PC: Proteolytic exposure of a cryptic site within collagen type iv is required for angiogenesis and tumor growth in vivo. J Cell Biol 2001; 154:1069-1079. (Pubitemid 34286185)
15. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74:413-417. (Pubitemid 26254571)
16. Duffy MJ, McCarthy K: Matrix metalloproteinases in cancer. Prognostic markers and targets for therapy (review). Int J Oncol 1998; 12:1343-1348. (Pubitemid 28239947)
17. Cho YR, Kwon HC, Suh SH, Lee JH, Kim SH, Choi HJ, Lee HS, Roh MS, Hwang TH, Kim JS, Kim HJ: Expressions of matrix metalloproteinase-7 and -9 and their prognostic significances in rectal cancer. Cancer Res Treat 2005; 37:354-359.
18. Jung M, Jeung HC, Lee SS, Park JY, Hong S, Ue SH, Noh SH, Chung HC, Rha SY: The clinical significance of ascitic fluid cea in advanced gastric cancer with ascites. J Cancer Res Clin Oncol 2010; 136:517-526.
19. Yajima K, Kanda T, Ohashi M, Wakai T, Nakagawa S, Sasamoto R, Hatakeyama K: Clinical and diagnostic significance of preoperative computed tomography findings of ascites in patients with advanced gastric cancer. Am J Surg 2006; 192:185-190. (Pubitemid 44066311)
20. Cho NH, Shim HS, Rha SY, Kang SH, Hong SH, Choi YD, Hong SJ, Cho SH: Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 2003; 44:560-566. (Pubitemid 37328632)
21. Lengyel E, Schmalfeldt B, Konik E, Spathe K, Halting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W: Expression of latent matrix metalloproteinase 9 (mmp-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001; 82:291-298. (Pubitemid 32730606)
22. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001; 7:3113-3119. (Pubitemid 32963832)
23. Lombard C, Saulnier J, Wallach J: Assays of matrix metalloproteinases (mmps) activities: A review. Biochimie 2005; 87:265-272. (Pubitemid 40387605)
24. Tuzun Y, Celik Y, Bayan K, Yilmaz S, Dursun M, Canonic F: Correlation of tumour markers in ascitic fluid and serum: Are measurements of ascitic tumour markers a futile attempt? J Int Med Res 2009; 37:79-86.
25. Mroczko B, Groblewska M, Lukaszewicz-Zajac M, Bandurski R, Kedra B, Szmitkowski M: Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (mmp-9) and tissue inhibitor of matrix metalloproteinases 1 (timp-1) in gastric cancer patients. Clin Chem Lab Med 2009; 47:1133-1139.
26. Emara M, Cheung PY, Grabowski K, Sawicki G, Wozniak M: Serum levels of matrix metalloproteinase-2 and -9 and conventional tumor markers (cea and ca 19-9) in patients with colorectal and gastric cancers. Clin Chem Lab Med 2009; 47:993-1000.
27. Staack A, Badendieck S, Schnorr D, Loening SA, Jung K: Combined determination of plasma mmp2, mmp9, and timp1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol 2006; 6:19.
28. Foda HD, Zucker S: Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 2001; 6:478-482. (Pubitemid 32422151)